Study Details
A Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FMS-like tyrosine kinase (FLT3) Mutation
Clinicaltrials.gov ID
Astellas Study ID
2215-CL-0301
EudraCT ID
2015-000140-42
Condition
Leukemia - AML
Phase
Phase 3
Age
18 years - N/A
Sex
Female & Male
Product
gilteritinib
Type
Interventional
Trial Dates
Oct 2015 - Jul 2024
Masking
None (Open Label)
Enrollment number
371
A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FMS-like tyrosine kinase (FLT3) Mutation? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site US10083
Evanston, United States, 60201
Site US10058
Oklahoma City, United States, 73104
Site JP81024
Okayama, Japan
Site FR33002
Le Chesnay Cedex, France, 78157
Site PL48004
Wroclaw, Poland, 50-367
Site US10001
Buffalo, United States, 14263
Site US10006
Chicago, United States, 60637
Site CA15004
Edmonton, Canada, T6G 2G3
Site US10087
Detroit, United States, 48201
Site TW88602
Taipei, Taiwan, Province of China, 114
Site US10085
Boston, United States, 02215
Site IL97209
Haifa, Israel, 31096
Site ES34014
Salamanca, Spain, 37007
Site TR90008
Izmir, Turkey, 35340
Site JP81026
Yoshida-gun, Japan
Site ES34009
Badalona, Spain, 08025
Site KR82004
Seoul, Republic of Korea, 120-752
Site GB44015
Plymouth, United Kingdom, PL6 8DH
Site FR33013
Brest, France, 29609
Site US10007
Houston, United States, 77030
Site US10046
Syracuse, United States, 13210
Site US10010
Philadelphia, United States, 19104
Site JP81004
Shinagawa-ku, Japan
Site US10041
Hershey, United States, 17033
Site CA15001
Hamilton, Canada, L8V 1C3
Site GB44003
Manchester, United Kingdom, M13 9WL
Site GB44013
Harrow, United Kingdom, HA1 3UJ
Site FR33009
Pessac, France, 33604
Site US10057
Minneapolis, United States, 55455
Site IL97203
Jerusalem, Israel, 91031
Site TW88601
Tainan, Taiwan, Province of China, 704
Site DE49004
Wurzburg, Germany, 97070
Site US10037
New York, United States, 10029
Site IT39011
Pavia, Italy, 27100
Site TW88611
Taipei, Taiwan, Province of China, 112
Site PL48003
Slupsk, Poland, 76-200
Site TW88609
Taichung City, Taiwan, Province of China, 40705
Site US10076
Orange, United States, 92868
Site DE49003
Marburg, Germany, 35043
Site JP81022
Shinjuku-ku, Japan
Site US10024
Durham, United States, 27710
Site US10044
Cleveland, United States, 44106
Site BE32008
Bruxelles, Belgium, 1000
Site US10084
Columbus, United States, 43210
Site US10080
Philadelphia, United States, 19107
Site ES34011
Barcelona, Spain, 08035
Site US10079
Stony Brook, United States, 11794
Site TR90004
Ankara, Turkey, 06500
Site JP81007
Kurashiki, Japan
Site US10086
Chicago, United States, 60637
Site US10063
Nashville, United States, 37232-0656
Site IT39007
Roma, Italy, 00189
Site DE49002
Munchen, Germany, 81737
Site ES34005
L'Hospitalet de Llobregat, Spain, 08907
Site US10078
Winston-Salem, United States, 27157
Site JP81002
Nagoya, Japan
Site US10023
Lebanon, United States, 03756-1000
Site JP81012
Sendai, Japan
Site JP81006
Yokohama, Japan
Site JP81016
Sapporo, Japan
Site US10011
Birmingham, United States, 35294-0006
Site US10081
Atlanta, United States, 30342
Site KR82011
Seoul, Republic of Korea, 156-707
Site JP81025
Kyoto, Japan
Site ES34015
Madrid, Spain, 28006
Site US10077
New Brunswick, United States, 08903
Site US10073
San Francisco, United States, 94143
Site JP81023
Akita, Japan
Site IL97201
Ashkelon, Israel, 78278
Site US10034
Boston, United States, 02114
Site ES34012
Barcelona, Spain, 08036
Site IL97210
Jerusalem, Israel, 91120
Site BE32001
Brugge, Belgium, 8000
Site JP81011
Osaka, Japan
Site BE32002
Yvoir, Belgium, 5530
Site IT39004
Palermo, Italy, 90146
Site TW88604
Kaohsiung, Taiwan, Province of China, 83301
Site DE49010
Tubingen, Germany, 72076
Site IT39002
Varese, Italy, 21100
Site JP81001
Fukuoka, Japan
Site KR82008
Seoul, Republic of Korea, 138-736
Site KR82003
Jeollanam-do, Republic of Korea, 519-809
Site CA15015
Toronto, Canada, M5G 2M9
Site JP81027
Shimotsuke, Japan
Site DE49011
Leipzig, Germany, 04103
Site FR33011
Angers, France, 49000
Site IT39001
Milan, Italy, 20132
Site BE32010
Antwerp, Belgium, 2060
Site IE35304
Dublin, Ireland, 9
Site KR82010
Busan, Republic of Korea, 602739
Site US10072
New York, United States, 10065
Site KR82009
Goyang, Republic of Korea, 602-715
Site TW88603
Taipei, Taiwan, Province of China, 10002
Site KR82005
Suwon-si, Republic of Korea, 443380
Site US10022
Boston, United States, 02215
Site US10027
Hackensack, United States, 07601
Site CA15016
Montreal, Canada, H3H 2R9
Site US10005
Baltimore, United States, 21201
Site IL97208
Rehovot, Israel, 76100
Site KR82002
Seoul, Republic of Korea, 137701
Site CA15003
Montreal, Canada, H1T 2M4
Site US10045
Gainesville, United States, 32610
Site JP81005
Chuo-ku, Japan
Site JP81003
Maebashi, Japan
Site IT39010
Brescia, Italy, 25126
Site US10012
Los Angeles, United States, 90095-1752
Site US10033
Maywood, United States, 60153
Site JP81021
Aomori, Japan
Site TR90001
Ankara, Turkey, 06100
Site JP81014
Osakasayama, Japan
Site KR82001
Seoul, Republic of Korea, 135710
Site JP81008
Nagasaki, Japan
Site FR33010
Lille, France, 59037
Site PL48002
Gdansk, Poland, 80-952
Site JP81009
Isehara, Japan
Site US10013
New York, United States, 10065
Site FR33008
Toulouse, France, 31059
Site ES34017
Valencia, Spain, 46026
Site US10067
New Haven, United States, 06504
Site PL48005
Opole, Poland, 45-372
Site ES34010
Barcelona, Spain, 08916
Site US10075
Westwood, United States, 66205
Site KR82007
Seoul, Republic of Korea, 110-744
Site TW88610
Taipei, Taiwan, Province of China, 10449
Site TW88606
Kaohsiung, Taiwan, Province of China, 112
Site GB44014
Bournemouth, United Kingdom, BH7 7DW
Site DE49009
Dresden, Germany, 01307
Site JP81018
Kobe, Japan
Site ES34016
Girona, Spain, 17007
Site US10008
New York, United States, 10032
Site US10048
New Orleans, United States, 70112
Site JP81010
Narita, Japan
Site US10014
Charleston, United States, 29425
Site JP81017
Tsukuba, Japan
Site US10074
Louisville, United States, 40202
Site IT39005
Bologna, Italy, 40138
Site JP81013
Kumamoto, Japan
Site FR33014
Rennes, France, 35033
Site US10035
Milwaukee, United States, 53226
Site TW88608
Taichung, Taiwan, Province of China, 404
Site TW88605
Taoyuan, Taiwan, Province of China, 33305
Site IL97206
Petah Tikva, Israel, 49100
Site JP81020
Kawagoe, Japan
Site US10054
Worcester, United States, 01655
The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website
© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.
POWERED BY:
